Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) have been assigned a consensus rating of “Buy” from the ten analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $19.48.

Several research firms recently issued reports on BLCM. BidaskClub raised shares of Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, April 17th. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 1st. Cantor Fitzgerald set a $10.00 target price on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 13th. Wells Fargo & Co upgraded shares of Bellicum Pharmaceuticals from a “market perform” rating to an “outperform” rating and lowered their target price for the company from $8.30 to $6.85 in a research note on Wednesday, April 11th. Finally, Citigroup boosted their target price on shares of Bellicum Pharmaceuticals from $24.00 to $27.00 and gave the company a “hold” rating in a research note on Friday, February 16th.

In other Bellicum Pharmaceuticals news, CFO Alan A. Musso sold 6,206 shares of the company’s stock in a transaction dated Friday, May 25th. The shares were sold at an average price of $7.97, for a total transaction of $49,461.82. Following the completion of the sale, the chief financial officer now directly owns 26,548 shares of the company’s stock, valued at $211,587.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 9.84% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of BLCM. Virtus Fund Advisers LLC acquired a new position in Bellicum Pharmaceuticals in the fourth quarter worth approximately $343,000. X Square Capital LLC acquired a new position in Bellicum Pharmaceuticals during the fourth quarter valued at approximately $544,000. Prosight Management LP acquired a new position in Bellicum Pharmaceuticals during the fourth quarter valued at approximately $2,534,000. Knott David M grew its holdings in Bellicum Pharmaceuticals by 12.8% during the first quarter. Knott David M now owns 67,653 shares of the biopharmaceutical company’s stock valued at $444,000 after purchasing an additional 7,669 shares during the last quarter. Finally, Vident Investment Advisory LLC grew its holdings in Bellicum Pharmaceuticals by 37.2% during the fourth quarter. Vident Investment Advisory LLC now owns 150,426 shares of the biopharmaceutical company’s stock valued at $1,265,000 after purchasing an additional 40,780 shares during the last quarter. 43.00% of the stock is owned by institutional investors and hedge funds.

BLCM traded up $0.52 during trading on Monday, hitting $9.85. 11,991 shares of the company’s stock were exchanged, compared to its average volume of 948,398. Bellicum Pharmaceuticals has a 1 year low of $5.02 and a 1 year high of $14.49. The company has a quick ratio of 6.75, a current ratio of 6.75 and a debt-to-equity ratio of 0.53. The company has a market cap of $408.15 million, a P/E ratio of -3.47 and a beta of 0.55.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.02. The company had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.08 million. research analysts anticipate that Bellicum Pharmaceuticals will post -2.45 earnings per share for the current year.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.